Slingshot Biosciences, Inc. has patented processes to manufacture "synthetic cells" that match the optical, biochemical, and physical features of virtually any cell type, in a shelf-stable, non-biohazardous and convenient format.
Through years of technology development and manufacturing optimization, we have built products that allow blood diagnostics to be applied to a broader range of unmet healthcare challenges. Moreover, our technology can accelerate the development of surrogate controls to any cell type (days vs. years for typical cell-based products).
In contrast to polystyrene-based options, FlowCytes perfectly match cells (autofluorescence, modulus, etc.) enabling a number of advanced applications for engineered cell therapies, general cell-calibration standards (such as blood typing), and beyond.
The result is a first-of-its-kind product that allows for single-step instrument set up and diagnosis, allowing for the preservation of valuable primary cell populations.
Synthetic cells that can match the scatter, fluorescent, and density properties of real cells such as PBMCs (peripheral blood mononuclear cells). Achieve newfound accuracy in calibrating instruments, assays, and cell engineering.
Match the scattering properties to virtually any cell types, even to rare malignancies and non-commercially viable controls. Development can be accomplished in weeks versus years for traditional cell line engineering.
FlowCytes are engineered to enable multiplexing of fluorophores, antibodies, proteins, and DNA/RNA. This modular platform vastly expands the applications of the technology.